Eli Lilly’s Taltz and Zepbound combo delivers superior results in landmark psoriatic arthritis trial

Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced ...
Healio

Lilly: Taltz plus Zepbound superior to monotherapy for psoriatic arthritis, weight loss

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...
GlobalData on MSN

Eli Lilly’s Taltz-Zepbound combo scores in late-stage PsA study

These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.
Rheumatology Advisor

Tirzepatide Added to Ixekizumab Improves Outcomes in Patients With PsA

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight

On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial ...

Lilly’s Zepbound Plus Arthritis Drug Taltz Eases Joint Pain

Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater ...
Medical Dialogues

Ixekizumab and Tirzepatide combo Improves PsA Control and Weight Loss, suggests study

The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...

Weight Loss Drugs Like Zepbound Could Help Treat Arthritis, Trial Shows

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.